Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

News Network

Virtual Tumor Board

Insights

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

Twitter

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors  

Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging  

Video content above is prompted by the following:

What is non–muscle-invasive bladder cancer (NMIBC)?

What are the common symptoms and signs of NMIBC?

What diagnostic procedures are typically used to confirm a case of NMIBC?

What is the economic burden of this disease for health care systems and insurance companies?

What are the main risk factors associated with the development of NMIBC? 

Smoking as a risk factor for the development of bladder cancer

No clear genetic association (that we know of so far)

What are the different stages and grades of NMIBC?Grabe-Heyne 2023

What is the importance of getting the stage correct? (PMID 38994181)

Ensuring appropriate treatment based on patient stage

How often do you feel that patients are incorrectly staged? How does that then affect the patient treatment journey?

Videos

Panelists discuss how emerging PD-1 and PD-L1 inhibitors could transform the treatment landscape for non–muscle-invasive bladder cancer, highlighting the importance of a multidisciplinary approach and ongoing clinical trials for high-risk patients.

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) presents with specific symptoms and diagnostic procedures, emphasize the significant economic burden on health care systems, and highlight key risk factors like smoking and occupational exposure while also addressing the critical importance of accurate staging for guiding treatment decisions and the potential consequences of incorrect staging on patient outcomes.

Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.

NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

Panelists discuss how the PD-1/PD-L1 pathway plays a crucial role in cancer immunotherapy, outlining its mechanisms of action and highlighting the agents currently being investigated for patients who are BCG-naive or unresponsive, including gene therapy and intravesical options.

Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC 

Panelists discuss how combining BCG with PD-1/PD-L1 inhibitors may enhance antitumor activity compared with using each agent alone, emphasizing the rationale for this combination therapy and its potential to evolve treatment strategies for non–muscle-invasive bladder cancer (NMIBC) while also considering the implications for patient flow in urology practice and the necessity of a multidisciplinary approach.

Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

Non–muscle-invasive bladder cancer (NMIBC) is characterized by tumors that have not invaded the muscle layer of the bladder. Common symptoms include hematuria, frequent urination, and dysuria. Diagnostic procedures typically involve cystoscopy, urine cytology, and imaging studies. The economic burden of NMIBC is significant due to frequent surveillance and treatment costs. Major risk factors include smoking and occupational exposures, with no clear genetic associations identified. Accurate staging is crucial for appropriate treatment, as incorrect staging can lead to suboptimal management and impact patient outcomes.

Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

Key Takeaways

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors